|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mhawech-Fauceglia P, Wang D, Samrao D,
Godoy H, Pejovic T, Liu S and Lele S: Pair-Box (PAX8) protein
positive expression is associated with poor disease outcome in
women with endometrial cancer. Br J Cancer. 107:370–374. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Verit FF and Yucel O: Endometriosis,
leiomyoma and adenomyosis: The risk of gynecologic malignancy.
Asian Pac J Cancer Prev. 14:5589–5597. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu Z and Ford BD: Uperegulation of erbB
recepters in rat brain after middle cerebrial arterial occlusion.
Neurosci Lett. 375:181–186. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Araújo A, Ribeiro R, Azevedo I, Coelho A,
Soares M, Sousa B, Pinto D, Lopes C, Medeiros R and Scagliotti GV:
Genetic polymorphisms of the epidermal growth factor and related
receptor in non-small cell lung cancer-a review of the literature.
Oncologist. 12:201–210. 2007. View Article : Google Scholar
|
|
6
|
Oshima CT, Lanzoni VP, Iriya K and Forones
NM: C-erbB-2 oncoprotein expression in gastric carcinoma:
Correlation with clinical stage and prognosis. Int J Biol Markers.
16:250–254. 2001.
|
|
7
|
Potti A, Forseen SE, Koka VK, Pervez H,
Koch M, Fraiman G, Mehdi SA and Levitt R: Determination of
HER-2/neu overexpression and clinical predictors of survival in a
cohort of 347 patients with primary malignant brain tumors. Cancer
Invest. 22:537–544. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rotter M, Block T, Busch R, Thanner S and
Höfer H: Expression of Her-2/neu in renal-cell carcinoma.
Correlation with histologic subtypes and differentiation. Int J
Cancer. 52:213–217. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Manavi M, Bauer M, Baghestanian M, Berger
A, Kucera E, Pischinger K, Battistutti W and Czerwenka K: Oncogenic
potential of c-erbB-2 and its association with c-K-ras in
premalignant and malignant lesions of the human uterine
endometrium. Tumour Biol. 22:299–309. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xi L, Satpathy M, Zhao Q, Qian W, Yang L
and Jiang H: HER-2/neu targeted delivery of a nanoprobe enables
dual photoacoustic and fluorescence tomography of ovarian cancer.
Nanomedicine. 10:669–677. 2014.
|
|
11
|
Carson WE, Parihar R, Lindemann MJ,
Personeni N, Dierksheide J, Meropol NJ, Baselga J and Caligiuri MA:
Interleukin-2 enhances the natural killer cell response to
Herceptin-coated Her2/neupositive breast cancer cells. Eur J
Immunol. 31:3016–3025. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Apte RS, Sinha D, Mayhew E, Wistow GJ and
Niederkorn JY: Cutting edge: Role of macrophage migration
inhibitory factor in inhibiting NK cell activity and preserving
immune privilege. J Immunol. 160:5693–5696. 1998.PubMed/NCBI
|
|
14
|
Rendon BE, Roger T, Teneng I, Zhao M,
Al-Abed Y, Calandra T and Mitchell RA: Regulation of human lung
adenocarcinoma cell migration and invasion by macrophage migration
inhibitory factor. J Biol Chem. 282:29910–29918. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liao H, Bucala R and Mitchell RA:
Adhesion-dependent signaling by macrophage migration inhibitory
factor (MIF). J Biol Chem. 278:76–81. 2003. View Article : Google Scholar
|
|
16
|
Amin MA, Volpert OV, Woods JM, Kumar P,
Harlow LA and Koch AE: Migration inhibitory factor mediates
angiogenesis via mitogen-activated protein kinase and
phosphatidylinositol kinase. Circ Res. 93:321–329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baumann R, Casaulta C, Simon D, Conus S,
Yousefi S and Simon HU: Macrophage migration inhibitory factor
delays apoptosis in neutrophils by inhibiting the
mitochondria-dependent death pathway. FASEB J. 17:2221–2230. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bacher M, Schrader J, Thompson N, Kuschela
K, Gemsa D, Waeber G and Schlegel J: Up-regulation of macrophage
migration inhibitory factor gene and protein expression in glial
tumour cells during hypoxic and hypoglycemic stress indicates a
critical role for angiogenesis in glioblastoma multiforme. Am J
Pathol. 162:11–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Repp AC, Mayhew ES, Apte S and Niederkorn
JY: Human uveal melanoma cells produce macrophage
migration-inhibitory factor to prevent lysis by NK cells. J
Immunol. 165:710–715. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krockenberger M, Dombrowski Y, Weidler C,
Ossadnik M, Hönig A, Häusler S, Voigt H, Becker JC, Leng L, Steinle
A, et al: Macrophage migration inhibitory factor contributes to the
immune escape of ovarian cancer by down-regulating NKG2D. J
Immunol. 180:7338–7348. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xia HH, Yang Y, Chu KM, Gu Q, Zhang YY, He
H, Wong WM, Leung SY, Yuen ST, Yuen MF, et al: Serum macrophage
migration-inhibitory factor as a diagnostic and prognostic
biomarker for gastric cancer. Cancer. 115:5441–5449. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
White ES, Flaherty KR, Carskadon S, Brant
A, Iannettoni MD, Yee J, Orringer MB and Arenberg DA: Macrophage
migration inhibitory factor and CXC chemokine expression in
non-small cell lung cancer: Role in angiogenesis and prognosis.
Clin Cancer Res. 9:853–860. 2003.PubMed/NCBI
|
|
23
|
Zheng J and Zhu YM: Expression of c-erbB-2
proto-oncogene in extrahepatic cholangiocarcinoma and its clinical
significance. Hepatobiliary Pancreat Dis Int. 6:412–415.
2007.PubMed/NCBI
|
|
24
|
Wu S, Lian J, Tao H, Shang H and Zhang L:
Correlation of macrophage migration inhibitory factor gene
polymorphism with the risk of early-stage cervical cancer and
lymphatic metastasis. Oncol Lett. 2:1261–1267. 2011.
|
|
25
|
Lambropoulou M, Stefanou D, Alexiadis G,
Tamiolakis D, Tripsianis G, Chatzaki E, Vandoros GP, Kiziridou A,
Papadopoulou E and Papadopoulos N: Cytoplasmic expression of
c-erbB-2 in endometrial carcinomas. Onkologie. 30:495–500. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bhatavdekar JM, Patel DD, Shah NG, Vora
HH, Suthar TP, Chikhlikar PR, Ghosh N and Trivedi TI: Prognostic
significance of immunohistochemically localized biomarkers in stage
II and stage III breast cancer. A multivariate analysis. Ann Surg
Oncol. 7:305–311. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim R, Arihiro K, Emi M, Tanabe K and
Osaki A: Potential role of HER-2; in primary breast tumor with bone
metastasis. Oncol Rep. 15:1477–1484. 2006.PubMed/NCBI
|
|
28
|
Pérez-Regadera J, Sánchez-Muñoz A,
De-la-Cruz J, Ballestín C, Lora D, García-Martín R, Mendiola C,
Alonso L, Alba E and Lanzós E: Negative prognostic impact of the
coexpression of epidermal growth factor receptor and c-erbB-2 in
locally advanced cervical cancer. Oncology. 76:133–141. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Toi M, Kashitani T and Tominaga T: Tumor
angiogenesis is an independent prognostic indicator in primary
breast carcinoma. Int J Cancer. 55:371–374. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Morrison C, Zanagnolo V, Ramirez N, Cohn
DE, Kelbick N, Copeland L, Maxwell GL and Fowler JM: HER-2 is an
independent prognostic factor in endometrial cancer: Association
with outcome in a large cohort of surgically staged patients. J
Clin Oncol. 24:2376–2385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bondza PK, Metz CN and Akoum A: Macrophage
migration inhibitory factor upregulates alpha(v)beta (3) integrin
and vascular endothelial growth factor expression in endometrial
adenocarcinoma cell line Ishikawa. J Reprod Immunol. 77:142–151.
2008. View Article : Google Scholar
|
|
32
|
Hagemann T, Robinson SC, Thompson RG,
Charles K, Kulbe H and Balkwill FR: Ovarian cancer cell-derived
migration inhibitory factor enhances tumor growth, progression and
angiogenesis. Mol Cancer Ther. 6:1993–2002. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nishihira J, Ishibashi T, Fukushima T, Sun
B, Sato Y and Todo S: Macrophage migration inhibitory factor (MIF):
Its potential role in tumor growth and tumor-associated
angiogenesis. Ann NY Acad Sci. 995:171–182. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Denz A, Pilarsky C, Muth D, Rückert F,
Saeger HD and Grützmann R: Inhibition of MIF leads to cell cycle
arrest and apoptosis in pancreatic cancer cells. J Surg Res.
160:29–34. 2010. View Article : Google Scholar
|
|
35
|
Verjans E, Noetzel E, Bektas N, Schütz AK,
Lue H, Lennartz B, Hartmann A, Dahl E and Bernhagen J: Dual role of
macrophage migration inhibitory factor (MIF) in human breast
cancer. BMC Cancer. 9(230)2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schulz R, Streller F, Scheel AH, Rüschoff
J, Reinert MC, Dobbelstein M, Marchenko ND and Moll UM: HER2/ErbB2
activates HSF1 and thereby controls HSP90 clients including MIF in
HER2-overexpressing breast cancer. Cell Death Dis. 5:e9802014.
View Article : Google Scholar : PubMed/NCBI
|
